Search - tctmd.com

Displaying 141 - 160 of 363

Presentation TCT 2014

Negatory: There are Logical Reasons for Why Renal Artery Denervation Failed in SIMPLICITY HTN-3!

Presenter: Sanjay Kaul, Ajay J. Kirtane, David E. Kandzari

September 13, 2014

$SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups$

Presentation TCT 2014

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Presenter: Patrick W. Serruys, Deepak L. Bhatt

September 13, 2014

News Industry News

Twelve-Month Data from St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

September 13, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

September 13, 2014

News Conference News TCT 2014

Experts Debate Future of Renal Denervation Therapy

September 13, 2014

News Industry News

Medtronic NC Euphora(TM) Coronary Balloon Receives FDA Clearance

September 11, 2014

News Industry News

Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014

September 10, 2014

News Conference News ESC 2014

ESC Congress 2014: Positive, Negative Findings Come on Background of Improving Outcomes Overall

Todd Neale

September 08, 2014

News Conference News ESC 2014

SYMPLICITY HTN-3: Renal Denervation Still Safe, Not Effective at 1 Year

Todd Neale

September 01, 2014

News Industry News

Kona Medical Initiates Clinical Trial of Non-Invasive Therapy for Resistant Hypertension

August 27, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Features

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

June 18, 2014

News Daily News

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

Yael L. Maxwell

June 11, 2014

News Daily News

SYMPLICITY HTN-2: La Denervación Renal es Segura y Eficaz a los 3 Años

Yael L. Maxwell

June 11, 2014

Presentation

Catheter-Based Renal Denervation for Treatment of Patients with Treatment-Resistant Hypertension

Presenter: Murray D. Esler

June 10, 2014

News Conference News EuroPCR 2014

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Caitlin E. Cox

May 28, 2014

News Conference News EuroPCR 2014

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Yael L. Maxwell

May 22, 2014

News Industry News

Preliminary Results From the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation Is Safe and Effective

May 22, 2014

Presentation EuroPCR 2014

Predictors of nonresponse to renal denervation in a real world population of patients with uncontrolled hypertension: Analysis of the Global SYMPLICITY Registry

Presenter: Felix Mahfoud

May 22, 2014

News Conference News EuroPCR 2014

Global SYMPLICITY Substudy Teases out Reasons for Non-response in Real-World Patients

Yael L. Maxwell

May 22, 2014

Advertisement

Negatory: There are Logical Reasons for Why Renal Artery Denervation Failed in SIMPLICITY HTN-3!

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Twelve-Month Data from St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

Experts Debate Future of Renal Denervation Therapy

Medtronic NC Euphora(TM) Coronary Balloon Receives FDA Clearance

Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014

ESC Congress 2014: Positive, Negative Findings Come on Background of Improving Outcomes Overall

SYMPLICITY HTN-3: Renal Denervation Still Safe, Not Effective at 1 Year

Kona Medical Initiates Clinical Trial of Non-Invasive Therapy for Resistant Hypertension

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

SYMPLICITY HTN-2: La Denervación Renal es Segura y Eficaz a los 3 Años

Catheter-Based Renal Denervation for Treatment of Patients with Treatment-Resistant Hypertension

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Preliminary Results From the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation Is Safe and Effective

Predictors of nonresponse to renal denervation in a real world population of patients with uncontrolled hypertension: Analysis of the Global SYMPLICITY Registry

Global SYMPLICITY Substudy Teases out Reasons for Non-response in Real-World Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content